ArticleFrontiers in psychiatry2024
Treatment of a schizophrenia patient on long-term super-dose antipsychotics: a case report.
Article in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Randomised controlled trial of clozapine in resistant schizophrenia and schizoaffective disorder.Journal of psychopharmacology (Oxford, England) · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Clozapine and chlorpromazine are widely used for treating schizophrenia. However, irregular medical follow-ups are common in patients with schizophrenia, potentially leading to long-term super-dose medication. Managing such cases poses significant challenges for clinical psychiatrists. Case presentation: This report describes a 24-year-old Han Chinese male diagnosed with schizophrenia who had been taking long-term super-doses of clozapine (18-107 tablets/day, 25 mg/tablet) and chlorpromazine (7-40 tablets/day, 50 mg/tablet) for five months due to irregular medical follow-ups. Upon hospitalization, the doses of antipsychotic drugs were gradually tapered, and the medication regimen was adjusted based on the patient's previous treatment history. Comprehensive health education about schizophrenia was also provided. The patient was followed for four years, during which his psychiatric symptoms remained under partial control. Conclusion: Clinicians must consider individual differences in the efficacy and adverse effects of antipsychotics and weigh the benefits and risks of combination therapy. Future efforts should focus on strengthening health education for patients with schizophrenia and their families to improve treatment compliance and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.